

## Special Issue

# Recent Advances in Novel Pneumococcal Vaccines

### Message from the Guest Editor

Prevention of pneumonia and invasive disease caused by *Streptococcus pneumoniae* is essential to avoid the high morbidity and mortality rates worldwide by this devastating human pathogen. New broader pneumococcal conjugate vaccines (PCVs) may partially solve this problem for a limited period of time although, alternative vaccines based in conserved and immunogenic protein antigens, DNA-based vaccines, whole cell vaccines and others preventive options that may increase the protection coverage are needed. This Special Issue will focus in the characterization of novel vaccines to prevent pneumococcal infections including the evaluation of the host immune response of newer PCVs and non-capsular based vaccines. The impact of vaccines reducing pneumococcal carriage and disease would be of interest. Contributions in the areas of microbiology, immunology and clinical epidemiology related to novel pneumococcal vaccines are welcome.  
Dr. Jose Yuste

---

### Guest Editor

Dr. Jose Enrique Yuste

Spanish Pneumococcal Reference Laboratory, National Center for Microbiology, Instituto de Salud Carlos III, Madrid, Spain

---

### Deadline for manuscript submissions

closed (31 January 2021)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/47495](https://mdpi.com/si/47495)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).